Sensei Biotherapeutics to Present at Upcoming Conferences
Sensei Biotherapeutics, Inc. (SNSE) will be presenting at Oppenheimer's 34th Annual Healthcare Life Sciences Conference and the 10th Annual Immuno-Oncology 360 Conference in February 2024. The company's management will present virtually at the Oppenheimer conference and in person at the IO360 conference in Brooklyn, NY. A webcast of the Oppenheimer presentation will be available on the Sensei website, with a replay available for 90 days after the event.
02/07/2024 - 07:30 AM
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024:
Oppenheimer’s 34 th Annual Healthcare Life Sciences Conference Wednesday, February 14, 2024, at 10:00 a.m. ET. Virtual
10 th Annual Immuno-Oncology 360 Conference (IO360) Thursday, February 29, 2024, at 11:10 a.m. ET Brooklyn, NY
A webcast of Sensei’s presentation at Oppenheimer will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available here.
About Sensei Biotherapeutics Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com , and follow the company on Twitter @SenseiBio and LinkedIn .
Investor Contact: Michael Biega Senior Director, Investor Relations Sensei Biotherapeuticsmbiega@senseibio.com
Media Contact: Joyce Allaire LifeSci AdvisorsJallaire@lifesciadvisors.com
When will Sensei Biotherapeutics, Inc. (SNSE) present at Oppenheimer's conference?
Sensei Biotherapeutics, Inc. (SNSE) will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:00 a.m. ET.
Where will Sensei Biotherapeutics, Inc. (SNSE) present at the IO360 conference?
Sensei Biotherapeutics, Inc. (SNSE) will present at the 10th Annual Immuno-Oncology 360 Conference (IO360) in Brooklyn, NY, on Thursday, February 29, 2024, at 11:10 a.m. ET.
Will the presentation at Oppenheimer's conference be available for viewing online?
Yes, a webcast of Sensei Biotherapeutics, Inc.'s (SNSE) presentation at Oppenheimer's conference will be available in the Investors section of the Sensei website.
How long will the webcast replay be available after the Oppenheimer conference?
The webcast replay will be available on the Sensei website for approximately 90 days following the Oppenheimer conference.
Sensei Biotherapeutics Inc
SNSE Rankings
#4942 Ranked by Stock Gains
SNSE Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About SNSE
sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit